Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.
about
Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutideChemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapiesThe use of exenatide in severely burned pediatric patients.Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells.Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis.Incretin therapy--present and future.The role of incretin therapy at different stages of diabetes.Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 DiabetesExpression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc.Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor AgonistsActing on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPERHerbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compoundsSitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside.Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge.Type 1 diabetes: etiology, immunology, and therapeutic strategies.Linagliptin: in type 2 diabetes mellitus.Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.Repaglinide: a review of its use in type 2 diabetes mellitus.Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis.The older patient with diabetes: a practical approach.Reversibility of endothelial dysfunction in diabetes: role of polyphenols.Unsaturated glycoceramides as molecular carriers for mucosal drug delivery of GLP-1.Glycemic variability: Clinical implications.Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes.Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medicationsNovel treatments for type 2 diabetesGIP: an inconsequential incretin or not?Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.Impact of body weight on antidiabetic treatment and predictors of weight control under real-world conditions: a 2-year follow-up of DiaRegis cohort.Postmeal increment in intact glucagon-like peptide 1 level, but not intact glucose-dependent insulinotropic polypeptide levels, is inversely associated with metabolic syndrome in patients with type 2 diabetes.Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.Metal-bound claMP Tag inhibits proteolytic cleavage.Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)
P2860
Q28081671-468B60D6-2BC0-421E-9DFB-7F9B64B7E490Q33624771-3659CFC5-DA61-4CB6-99A8-F6C581DEE067Q34153353-92304F3E-5451-435F-9FE4-1B7F4811853CQ34468359-CBBFF1EE-7774-4B36-ACE2-C61641BAACADQ35565133-3FE7E86D-1AC7-4B6F-B79C-A42CD3B94064Q35627261-4B2A1374-024A-4E46-8FB9-482BCC37DC83Q35760283-0E184DE1-309F-4E8A-A42C-26A8E2431AF0Q35760288-C8E2F104-F753-4D75-ACFC-7A16D225E33BQ35909303-8024549F-DA18-4A79-A194-B528DAE80255Q36032335-5BCFA6C0-24C7-4921-A959-605EABA47B4EQ36073461-D59083C4-CE2C-4315-BF9A-DDA65B5500C7Q36800401-BFC39826-5B30-495B-A447-E624B231F861Q36801780-C6251271-64CA-44DD-8EE7-5C7EE1BDD6F9Q37033531-74A84E85-1D58-4854-9F5A-075807037A85Q37425253-41C16AAF-65D0-4724-9641-131353DC698BQ37682555-BC6E3DA4-8C6E-42CF-9B4B-62CEA7E7765AQ37780914-71B3FF84-691E-4B76-B606-A4B35C784A44Q37830198-8029E110-2F84-4219-9A5C-882CBB0AA55DQ37858521-D7EFCAAD-7111-4C56-A09A-D42546915FEDQ37941683-0D8E3BF8-34F1-4095-93F1-43EAF2DA3343Q37977979-42DEF795-7077-4EF1-B7D5-25E3CE797A0BQ38110890-0A2ECF55-6257-4967-B56E-75A36727D1B2Q38152414-A75D6458-5031-48CE-B8DD-DF695A6DE9F2Q38855635-EE67F8D2-06AC-4CD1-A6F7-00A47E212C80Q39039567-0D20A26C-A9C5-4365-A57E-25C6BE5FC602Q39364360-9F9133B2-A151-48D7-8CBA-4A1B25FE5140Q40718402-6D035181-44B4-4093-954F-DAFDC8C1FA51Q41184651-873E892D-375A-4927-AC93-DA07843C97B6Q42171159-F28EC1E1-581C-4F88-A644-BF18F3315035Q42231156-11A12DA2-1343-4AAC-A518-194B531F7ACDQ42568158-8C2CE83D-560F-4A7E-83D4-989286C89C3CQ42745259-C248FFDA-5845-4DC8-AD89-FC5270985431Q43023352-444E73C0-0A5D-49AD-92C6-AED8D573F71CQ47370986-2FF1E20F-BBCA-404A-8B98-D93237A23C5FQ48190264-0B571349-C130-4F2F-A7BD-17BB6F690685Q48864523-F6C33D9E-C186-4D90-8A24-4019CFC037CAQ50624935-45DDAE8A-5661-4B98-A57F-F362AB01C90BQ57192174-85CA0D2F-0D4E-48BA-BAAE-8BA0A6AF70DA
P2860
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting Incretins in Type 2 ...... Agonists and DPP-4 Inhibitors.
@en
Targeting Incretins in Type 2 ...... Agonists and DPP-4 Inhibitors.
@nl
type
label
Targeting Incretins in Type 2 ...... Agonists and DPP-4 Inhibitors.
@en
Targeting Incretins in Type 2 ...... Agonists and DPP-4 Inhibitors.
@nl
prefLabel
Targeting Incretins in Type 2 ...... Agonists and DPP-4 Inhibitors.
@en
Targeting Incretins in Type 2 ...... Agonists and DPP-4 Inhibitors.
@nl
P2860
P356
P1476
Targeting Incretins in Type 2 ...... Agonists and DPP-4 Inhibitors.
@en
P2093
Matthew Gilbert
Richard E Pratley
P2860
P356
10.1900/RDS.2008.5.73
P577
2008-08-10T00:00:00Z